Rogier Mous

1.4k total citations · 1 hit paper
35 papers, 723 citations indexed

About

Rogier Mous is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Rogier Mous has authored 35 papers receiving a total of 723 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Genetics, 18 papers in Pathology and Forensic Medicine and 15 papers in Oncology. Recurrent topics in Rogier Mous's work include Chronic Lymphocytic Leukemia Research (21 papers), Lymphoma Diagnosis and Treatment (18 papers) and CAR-T cell therapy research (11 papers). Rogier Mous is often cited by papers focused on Chronic Lymphocytic Leukemia Research (21 papers), Lymphoma Diagnosis and Treatment (18 papers) and CAR-T cell therapy research (11 papers). Rogier Mous collaborates with scholars based in Netherlands, United States and United Kingdom. Rogier Mous's co-authors include Erik Mul, Martine E.D. Chamuleau, Sandra van Wetering, Jaap Jan Zwaginga, Jaap D. van Buul, Ingrid Lommerse, Jean Paul ten Klooster, Peter L. Hordijk, Kim Linton and Pieternella J. Lugtenburg and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Rogier Mous

32 papers receiving 713 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

2021 212 citations Martin Hutchings, Rogier Mous et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rogier Mous Netherlands	11	392	308	245	174	155	35	723
Nadja Zaborsky Austria	18	336 0.9×	138 0.4×	386 1.6×	256 1.5×	283 1.8×	49	945
Kyle A. Beckwith United States	10	222 0.6×	300 1.0×	269 1.1×	391 2.2×	164 1.1×	18	681
Daniela Gottardi Italy	11	193 0.5×	379 1.2×	405 1.7×	605 3.5×	353 2.3×	19	1.0k
Elisabeth Oelmann Germany	16	268 0.7×	141 0.5×	242 1.0×	88 0.5×	348 2.2×	31	773
Olga Plotnikova United States	7	323 0.8×	487 1.6×	121 0.5×	202 1.2×	349 2.3×	9	853
Elisa ten Hacken United States	18	210 0.5×	346 1.1×	420 1.7×	664 3.8×	333 2.1×	36	941
Patrik Georgii‐Hemming Sweden	14	244 0.6×	90 0.3×	133 0.5×	68 0.4×	409 2.6×	17	778
Katherine Chung United States	9	200 0.5×	223 0.7×	236 1.0×	56 0.3×	167 1.1×	13	661
Natalie Fadle Germany	16	114 0.3×	115 0.4×	301 1.2×	116 0.7×	353 2.3×	38	780
Linda W. Horton United States	9	239 0.6×	144 0.5×	175 0.7×	183 1.1×	253 1.6×	12	595

Countries citing papers authored by Rogier Mous

Since Specialization

Citations

This map shows the geographic impact of Rogier Mous's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rogier Mous with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rogier Mous more than expected).

Fields of papers citing papers by Rogier Mous

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rogier Mous. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rogier Mous. The network helps show where Rogier Mous may publish in the future.

Co-authorship network of co-authors of Rogier Mous

This figure shows the co-authorship network connecting the top 25 collaborators of Rogier Mous. A scholar is included among the top collaborators of Rogier Mous based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rogier Mous. Rogier Mous is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Trněný, Marek, Raúl Córdoba, Sven de Vos, et al.. (2025). ABCL-404: Epcoritamab + R-ICE in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Eligible For Autologous Stem Cell Transplantation (ASCT): EPCORE NHL-2. Clinical Lymphoma Myeloma & Leukemia. 25. S736–S736.

Brink, Mirian, Martine E.D. Chamuleau, Rolf E. Brouwer, et al.. (2023). R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study. American Journal of Hematology. 99(2). 216–222. 11 indexed citations

Kong, Weikaixin, Christian Brieghel, Geir E. Tjønnfjord, et al.. (2023). S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL. HemaSphere. 7(S3). e92046ec–e92046ec. 1 indexed citations

Mous, Rogier, Roos J. Leguit, Lisette van de Corput, et al.. (2022). Hematologic malignancies following immune checkpoint inhibition for solid tumors. Cancer Immunology Immunotherapy. 72(1). 249–255. 5 indexed citations

Groen, Ruben A. L. de, Anke van den Berg, Patty M. Jansen, et al.. (2022). Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach. Cancers. 14(8). 1857–1857. 6 indexed citations

Brink, Mirian, Joost S.P. Vermaat, Josée M. Zijlstra, et al.. (2021). Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study. Blood Advances. 5(15). 2958–2964. 16 indexed citations

Hutchings, Martin, Rogier Mous, Michael Roost Clausen, et al.. (2021). Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. The Lancet. 398(10306). 1157–1169. 212 indexed citations breakdown →

Hutchings, Martin, Rogier Mous, Michael Roost Clausen, et al.. (2021). SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA: SAFETY PROFILE AND ANTI‐TUMOR ACTIVITY. Hematological Oncology. 39(S2). 1 indexed citations

Clausen, Michael Roost, Pieternella J. Lugtenburg, Martin Hutchings, et al.. (2021). Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.. Journal of Clinical Oncology. 39(15_suppl). 7518–7518. 14 indexed citations

10.

Stein, Eytan M., Jörg Chromik, Cecilia Carpio, et al.. (2021). Siremadlin (HDM201) Is Well Tolerated and Demonstrates Clinical Activity in Patients with Acute Myeloid Leukemia Who Have Relapsed after Allogeneic Stem Cell Transplantation: A Subset Analysis of Safety and Preliminary Efficacy. Blood. 138(Supplement 1). 3417–3417. 5 indexed citations

11.

Jongen‐Lavrencic, Mojca, Junichiro Yuda, Rogier Mous, et al.. (2020). AML-058: First-In-Human Study of a Trail Receptor Agonist Fusion Protein, Eftozanermin Alfa, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 20. S177–S177. 2 indexed citations

12.

Hutchings, Martin, Pieternella J. Lugtenburg, Rogier Mous, et al.. (2020). Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.. Journal of Clinical Oncology. 38(15_suppl). 8009–8009. 19 indexed citations

13.

Chamuleau, Martine E.D., Coreline N. Burggraaff, Marcel Nijland, et al.. (2018). MYC Rearrangement Positive Large B-Cell Lymphoma Patients Can Be Treated Successfully with R-CHOP Plus Lenalidomide: Results of a Multicentre Phase II HOVON Trial. SSRN Electronic Journal. 1 indexed citations

14.

Hillmen, Peter, Arnon P. Kater, John F. Seymour, et al.. (2018). High, durable minimal residual disease negativity (MRD–) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.. Journal of Clinical Oncology. 36(15_suppl). 7508–7508. 3 indexed citations

15.

Oostvogels, Rimke, Margot Jak, Reinier Raymakers, Rogier Mous, & Monique C. Minnema. (2018). Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients. British Journal of Haematology. 183(1). 60–67. 21 indexed citations

16.

Visser, Hein P. J., Michel van Gelder, Mark‐David Levin, et al.. (2017). Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands. Clinical Lymphoma Myeloma & Leukemia. 18(1). 52–57. 6 indexed citations

17.

Mous, Rogier, et al.. (2016). ⁸⁹Zr‐rituximab PET/CT to detect neurolymphomatosis. American Journal of Hematology. 91(6). 649–650. 3 indexed citations

18.

Jak, Margot, Rogier Mous, Ester B. M. Remmerswaal, et al.. (2009). Enhanced formation and survival of CD4⁺CD25^hiFoxp3⁺T-cells in chronic lymphocytic leukemia. Leukemia & lymphoma. 50(5). 788–801. 91 indexed citations

19.

Mous, Rogier, et al.. (2008). Adequate synapse formation between leukemic B cells and effector T cells following stimulation with artificial TCR ligands. Leukemia & lymphoma. 49(8). 1592–1602. 3 indexed citations

20.

Mous, Rogier, Philip Savage, Ester B. M. Remmerswaal, et al.. (2006). Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA/CMV complexes. Leukemia. 20(6). 1096–1102. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact